ESC Congress 2026 Abstract · Oct 26, 2026
Tirzepatide versus dulaglutide in type 2 diabetes: a comparative meta-analysis of cardiometabolic outcomes and safety
By Calderon Fernandez A, Martinez Topete S, Leal Samaniego D et al.
Background: Incretin-based therapies are central to type 2 diabetes (T2D) management, and glucagon-like peptide-1 receptor agonists improve glycaemic control and reduce cardiovascular risk. Dulaglutide has demonstrated cardiovascular benefit, making it a clinically relevant active comparator. Tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, shows greater metabolic efficacy in head-to-head trials, but its comparative cardiometabolic and safety profile versus dulaglutide has not been fully synthesised. Purpose: To compare cardiometabolic effects, cardiovascular outcomes, and safety of tirzepatide versus dulaglutide in adults with T2D. Methods: PubMed and Embase were searched through 15 February 2026 for randomised controlled trials (RCTs) comparing tirzepatide with dulaglutide in patients with type 2 diabetes. Random-effects models pooled mean differences (MD) with 95% confidence intervals (CI). Effect estimates were derived from placebo-adjusted least-squares mean (LSM) changes and corresponding standard errors. Exploratory analyses assessed effects by follow-up duration. Heterogeneity was assessed using the Chi-squared test and I² statistic. Results: Three RCTs, including 14,066 patients (7,274 in tirzepatide group and 6,792 in dulaglutide groups), were analysed. Tirzepatide reduced HbA1c (MD -1.13; CI -1.83 to -0.42), bodyweight (MD -8.46 kg; CI -11.79 to -5.13) and triglycerides (MD -21.34 mg/dL; CI -36.50 to -6.17) versus dulaglutide. Systolic blood pressure was numerically lower but not significant (MD -5.73 mmHg; CI -13.07 to 1.62). Low-density lipoprotein cholesterol effects were not significant overall and varied by follow-up duration. In analyses of major cardiovascular outcomes, no significant differences in myocardial infarction (RR 0.87; CI 0.75 to 1.01) or stroke (RR 0.92; CI 0.77 to 1.10) were found between groups. All-cause mortality was lower with tirzepatide (RR 0.85; CI 0.76 to 0.94), driven by the cardiovascular outcomes trial. Adverse events leading to treatment discontinuation were more frequent with tirzepatide (RR 1.31; CI 1.19 to 1.43). Conclusion(s): In adults with T2D, tirzepatide produced greater improvements in HbA1c, bodyweight and triglycerides than dulaglutide, while effects on systolic blood pressure and low-density lipoprotein cholesterol were not significant overall and appeared time-dependent. Myocardial infarction and stroke were not significantly different between groups. All-cause mortality was lower with tirzepatide, driven by the cardiovascular outcomes trial, whereas smaller short-term trials contributed no mortality events. Higher discontinuation due to adverse events underscores the need to balance metabolic benefit against tolerability and to refine long-term clinical outcome estimates with continued follow-up.
doi.org/10.1093/eurheartj/ehag785.4190Open accessInterventions